"This trial met its primary end point and demonstrated superiority of fingolimod, both groups, over interferon beta1-a," Jeffrey Cohen, MD, from the Mellen Center at the Cleveland Clinic Foundation, in Ohio, told attendees here. "The relapse rate was reduced by 52% in the 0.5-mg group and 38% in the 1.23-mg group, and both groups showed reduced [magnetic resonance imaging] MRI lesion activity."
In general, the drug was well tolerated, with a safety profile similar to what has already been seen in other fingolimod studies, he noted. The lower dose appeared to be better tolerated than the higher dose and may be more effective.
Users browsing this forum: No registered users